PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.68
−1.05%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.07
- Revenue estimate
- $98.2M
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- -$0.16
- EPS estimate
- -$0.11
- Revenue actual
- $84.7M
- Revenue estimate
- $85.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -81.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $12
- PT range
- $10 – $14
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | -$0.11 | -$0.16 | Miss -45.85% | $84.7M |
| Jul 30, 2026 | -$0.18 | -$0.21 | Miss -19.60% | $74.3M |
| Apr 30, 2026 | -$0.27 | -$0.37 | Miss -37.04% | $58.3M |
| Feb 26, 2026 | -$0.09 | -$0.29 | Miss -222.22% | $57.6M |
| Oct 30, 2025 | -$0.30 | -$0.15 | Beat 50.00% | $49.5M |
| Aug 7, 2025 | -$0.76 | -$0.79 | Miss -3.95% | $39.5M |
| May 1, 2025 | -$1.06 | -$1.07 | Miss -0.94% | $28.5M |
| Mar 6, 2025 | -$1.29 | -$0.79 | Beat 38.76% | $29.7M |
| Nov 7, 2024 | -$1.57 | -$1.32 | Beat 15.92% | $16.4M |
| Aug 8, 2024 | -$1.20 | -$1.25 | Miss -4.17% | $7.3M |
| May 9, 2024 | -$1.43 | -$1.42 | Beat 0.70% | $1.9M |
| Mar 7, 2024 | -$0.92 | -$0.80 | Beat 13.04% | $682.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027